Neuroendocrinology News

Real-world data from the long-term ACROSTUDY show the growth hormone receptor agonist pegvisomant is safe and effective, with a low incidence of liver enzyme elevation and no increase in tumor size for most patients with acromegaly.

An international panel reached consensus for pre- and postoperative endocrine testing to manage adults undergoing transsphenoidal surgery, including measurement of prolactin and insulin-like growth factor I levels for all pituitary tumors.

Adults with acromegaly reported improved quality of life and more work productivity after transitioning from injectable somatostatin receptor ligands to oral octreotide capsules, according to MPOWERED phase 3 trial data.

The FDA accepted for review a new drug application for the steroidogenesis inhibitor levoketoconazole for the treatment of endogenous Cushing’s syndrome, according to an industry press release.

Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide maintained response for an additional 48 weeks with no new safety signals observed, data from an open-label extension study show.

Adults treated for acromegaly at a medical center in Turkey do not have an increased risk for cancer compared with the general population, according to study findings published in Endocrine Practice.

Central hypothyroidism is prevalent in about 1 in 2 adults with Cushing’s syndrome, and thyroid function can be restored after curative surgery for most patients, according to study findings.

Adults with acromegaly have a sixfold higher incidence rate of carpal tunnel syndrome compared with the general population, with most diagnosed and undergoing surgery before the acromegaly diagnosis, according to a retrospective study.

Adults with a high BMI have an increased risk for pituitary adenoma, with the risk even greater for those with a high BMI during early adulthood, according to findings published in the Journal of Clinical Endocrinology & Metabolism.

Nearly 20% of pediatric brain tumors occur in the pituitary region, and more than two-thirds of pituitary region tumors were present in girls, according to study findings published in Pituitary.